These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6733714)

  • 1. Development of selectively acting platinum complexes.
    Schönenberger H; Wappes B; Jennerwein M; Berger M
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():125-30. PubMed ID: 6733714
    [No Abstract]   [Full Text] [Related]  

  • 2. 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
    Knebel NG; von Angerer E
    J Med Chem; 1991 Jul; 34(7):2145-52. PubMed ID: 2066987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
    Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
    Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid hormone receptors in mammary carcinoma: the effect of tamoxifen.
    Koenders AJ; Beex LV; Geurts-Moespot J; Benraad TJ
    Eur J Cancer (1965); 1980; Suppl 1():63-6. PubMed ID: 7318871
    [No Abstract]   [Full Text] [Related]  

  • 5. Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma.
    Wappes B; Jennerwein M; von Angerer E; Schönenberger H; Engel J; Berger M; Wrobel KH
    J Med Chem; 1984 Oct; 27(10):1280-6. PubMed ID: 6481764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
    von Angerer E; Birnböck H; Knebel N
    Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
    Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
    J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
    Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
    Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Synthesis of platinum complexes of 2-aminoalkylpyridine as carrier ligand and their antitumor activities].
    Morikawa K; Honda M; Endoh K; Matsumoto T; Akamatsu K; Mitsui H; Koizumi M
    Yakugaku Zasshi; 1988 Apr; 108(4):317-24. PubMed ID: 3216326
    [No Abstract]   [Full Text] [Related]  

  • 10. Carrier mediated action of platinum complexes on estrogen receptor positive tumors.
    Knebel N; Schiller CD; Schneider MR; Schönenberger H; von Angerer E
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):293-9. PubMed ID: 2702983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine](sulfato)platinum-(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties.
    Gust R; Burgemeister T; Mannschreck A; Schönenberger H
    J Med Chem; 1990 Sep; 33(9):2535-44. PubMed ID: 2391694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new drugs for endocrine tumour chemotherapy.
    von Angerer E
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():147-53. PubMed ID: 6547370
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
    Reile H; Spruss T; Müller R; Gust R; Bernhardt G; Schönenberger H; Engel J
    Arch Pharm (Weinheim); 1990 May; 323(5):301-6. PubMed ID: 2383173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
    Gust R; Faderl M; Schönenberger H
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening procedure for the development of mammary tumour-inhibiting anti-oestrogens.
    Hartmann RW
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():155-61. PubMed ID: 6329512
    [No Abstract]   [Full Text] [Related]  

  • 16. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
    Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
    J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.
    Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW
    J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and P-388 antitumor properties of the four diastereomeric 1-hydroxy-3,4-diaminocyclohexane-Cl2PtII complexes.
    Witiak DT; Rotella DP; Wei Y; Filppi JA; Gallucci JC
    J Med Chem; 1989 Jan; 32(1):214-7. PubMed ID: 2909734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New platinum (II) and platinum (IV) complexes with 1,2-diaminocyclohexane. Synthesis and in vitro and in vivo antitumour evaluation.
    Craciunescu DG; Furlani Candiani A; Scarcia V; Doadrio A; Ghirvu C
    J Pharm Belg; 1985; 40(2):79-84. PubMed ID: 4009393
    [No Abstract]   [Full Text] [Related]  

  • 20. N,N'-Dialkyl-1,2-bis(hydroxyphenyl)ethylenediamines and N,N-dialkyl-4,5-bis(4-hydroxyphenyl)imidazolidines: syntheses and evaluation of their mammary tumor inhibiting activity.
    von Angerer E; Egginger G; Kranzfelder G; Bernhauer H; Schönenberger H
    J Med Chem; 1982 Jul; 25(7):832-7. PubMed ID: 6809943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.